ENZYME IMMUNOASSAYS FOR THE DIAGNOSIS OF TICK-BORNE ENCEPHALITIS

Tick-Borne Encephalitis Virus (TBEV)

EIA TBE Virus IgG and IgM kits are optimized and validated for detection of IgG and IgM antibodies in human serum, plasma and cerebrospinal fluid.
EIA TBEV Ig kit is optimized and validated for detection of total antibodies in sera of all vertebrates (except mice).
Tick-borne encephalitis is an endemic disease occurring in some parts of Europe and Asia. It is caused by a single-stranded RNA virus from the *Flaviviridae* family. The tick-borne encephalitis virus (TBEV) is transmitted mainly by ticks.

A typical infection shows a two-stage course of the disease following an incubation period ranging from 4–20 days. First, a prodromal stage with flu-like symptoms develops (fever, strong headache, muscle ache, torpidity). After a decrease in non-specific symptoms, approximately 10% of cases include a second stage of infection in which neurological signs of the disease can develop (high temperature, severe headache, emesis, torpidity and meningo-encephalitic symptoms). An acute stage of tick-borne encephalitis lasts for 1–3 weeks. A severe course of the disease, with long-lasting ill effects, may occur in seniors.

**Diagnosis of infection:**
- Diagnosis of the disease is based on epidemiological anamnesis, clinical manifestation and laboratory tests
- Direct detection of the virus is not feasible for routine diagnostics
- Serology and examination of cerebrospinal fluid are the most important diagnostic tool of tick-borne encephalitis

**Diagnostic value of different antibody classes:**

**IgM:**
- Marker of acute infection
- Occasionally can persist up to 10 months after infection

**IgG:**
- Anamnestic or post-vaccination antibodies
- Persist for years ensuring protection against infection
- IgG avidity reflects the stage of infection
Anti-TBEV IgM antibodies are usually detectable after the prodromal stage. Anti-TBEV IgG antibodies are detectable simultaneously or a few days after the appearance of IgM antibodies.

**Antibody Response**

### Antibody response during TBEV infection

![Graph showing antibody response during TBEV infection]

- **Acute infection**
- **Prodromal stage**
- **Incubation period**

**Antibody titer**

- **IgM**
- **IgG**

**Incubation period**

- **2**
- **4**
- **6**
- **8**

**Prodromal stage**

- **3**
- **4**
- **5**
- **6**
- **1**
- **2**

**Borderline**

**Antibody titer**

- **1st dose**
- **2nd dose**
- **3rd dose**

**Post-vaccination antibody response**

![Graph showing post-vaccination antibody response]

- **1st dose**
- **2nd dose**
- **3rd dose**

**Clinical Application**

- **Diagnostics of tick-borne encephalitis infection by detection of IgM and IgG specific antibodies against TBEV in serum and cerebrospinal fluid**
- **Monitoring and quantitative detection of post-TBEV vaccine antibody titre**
- **Monitoring total antibody titre in sera of all vertebrates (except mice) against TBEV in serum (EIA TBEV Ig)**
**Test Principle**

The EIA TBE Virus IgG and IgM assays are based on a sandwich type of ELISA method.

**Summary of EIA Protocol**

<table>
<thead>
<tr>
<th>Step No.</th>
<th>Test steps</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Dilute samples serum/plasma (1+100)</td>
</tr>
<tr>
<td>2</td>
<td>Incubate 10 minutes at lab.temperature</td>
</tr>
<tr>
<td>3</td>
<td>Pipette Controls and diluted samples 100 µl Blank = 100 µl Sample diluent</td>
</tr>
<tr>
<td>4</td>
<td>Incubate 30 minutes at 37°C</td>
</tr>
<tr>
<td>5</td>
<td>Aspirate and wash the wells 5 times</td>
</tr>
<tr>
<td>6</td>
<td>Add 100 µl Conjugate Including blank</td>
</tr>
<tr>
<td>7</td>
<td>Incubate 30 minutes at 37°C</td>
</tr>
<tr>
<td>8</td>
<td>Aspirate and wash the wells 5 times</td>
</tr>
<tr>
<td>9</td>
<td>Add 100 µl Substrate (TMB-Complete) Including blank</td>
</tr>
<tr>
<td>10</td>
<td>Incubate 15 minutes at 37°C</td>
</tr>
<tr>
<td>11</td>
<td>Add 100 µl Stopping solution Including blank</td>
</tr>
<tr>
<td>12</td>
<td>Read colour intensity at 450 nm</td>
</tr>
</tbody>
</table>

EIA TBEV Ig has different EIA protocol (total assay time 2.5 hours).

**Antigens**

Purified and inactivated native TBEV antigens.

**User Comfort**

- Ready-to-use components
- Colour-coded components
- Interchangeable components
- Breakable colour-coded microplate strips
- CUT-OFF included
- Semiquantitative evaluation of results (Index of Positivity)
- Quantitative evaluation of IgG antibodies (U/ml)
- Conversion to Vienna units possible
- Easy assay procedure
Advantages

- Identical assay procedure
- High diagnostic specificity and sensitivity
- High reproducibility
- High dynamics of antibody response
- Short total assay time
- Avidity test available
- Sample diluent contains RF sorb (EIA TBE Virus IgM)
- Ready for automation
- Customer support

Clinical Data

Acute infection – IgM and IgG antibodies titres and IgG avidity

**IgM antibody titer**
acute infection (n =47)

**IgG antibody titer**
acute infection (n = 47)

**IgG avidity**
acute infection (n = 47)

<table>
<thead>
<tr>
<th>ELISA</th>
<th>Diagnostic Sensitivity</th>
<th>Diagnostic Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>EIA TBE Virus IgG</td>
<td>98.7%</td>
<td>97.7%</td>
</tr>
<tr>
<td>EIA TBE Virus IgM</td>
<td>96.6%</td>
<td>98.9%</td>
</tr>
<tr>
<td>EIA TBEV Ig</td>
<td>97.7%</td>
<td>95.7%</td>
</tr>
</tbody>
</table>

Results Interpretation

<table>
<thead>
<tr>
<th>IgM</th>
<th>IgG</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>–</td>
<td>acute infection (very early stage)</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>acute infection</td>
</tr>
<tr>
<td>–</td>
<td>+</td>
<td>anamnestic or post-vaccination antibodies</td>
</tr>
<tr>
<td>–</td>
<td>–</td>
<td>specific antibodies were not proven</td>
</tr>
</tbody>
</table>

Test Characteristics

Index of Positivity (IP)

Index of Avidity (IA) %
### ELISA

<table>
<thead>
<tr>
<th>Cat. No.</th>
<th>Product</th>
<th>No. of Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBG096</td>
<td>EIA TBE Virus IgG</td>
<td>96</td>
</tr>
<tr>
<td>TBM096</td>
<td>EIA TBE Virus IgM</td>
<td>96</td>
</tr>
<tr>
<td>TBE096</td>
<td>EIA TBEV Ig</td>
<td>96</td>
</tr>
</tbody>
</table>

### CFT

<table>
<thead>
<tr>
<th>Cat. No.</th>
<th>Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBEKF1</td>
<td>TBEV – CF – Ag lyophil. (1 ml)</td>
</tr>
<tr>
<td>KFA00</td>
<td>CF – AMBOCEPTORset (0.5 ml)</td>
</tr>
<tr>
<td>KFA01</td>
<td>CF – AMBOCEPTORset (1 ml)</td>
</tr>
<tr>
<td>KFC001</td>
<td>CF – COMPLEMENT (1 ml)</td>
</tr>
</tbody>
</table>

---

**Contact**

TestLine Clinical Diagnostics Ltd.
Krizikova 68
612 00 Brno, Czech Republic
Tel.: +420 549 121 209 (218)
Fax: +420 541 243 390
E-mail: trade@testlinecd.com

www.testlinecd.com

Company is certified to the quality management system standards ISO 9001 and ISO 13485 for in vitro diagnostics.